Lafutidine changes levels of somatostatin, calcitonin gene-related peptide, and secretin in human plasma.
We examined the effects of the histamine H2-receptor antagonist, lafutidine, on the levels of gastrointestinal peptides (somatostatin, calcitonin gene-related peptide (CGRP), gastrin, secretin, and motilin) in plasma from healthy subjects. After a single oral administration of lafutidine (10 mg), the plasma lafutidine level (186 +/- 13.4ng/ml) was highest in the 60-min sample after administration and then the plasma level fell. Lafutidine caused significant increase in plasma somatostatin levels at 20 to 120 min and in CGRP levels at 40 to 120 min, compared with a placebo group. The physiological release of plasma secretin was reduced by administration of lafutidine, but the medicine did not alter the level of gastrin or motilin. These results suggest that the pharmacological effects of lafutidine on regulation of gastrointestinal functions closely relate to changes of somatostatin-, CGRP- and secretin-immunoreactive substance levels in human plasma.
Itoh
Hiroki
H
Department of Clinical Pharmacy, Oita Medical University, Hasama-machi, Japan. itoh@oita-med.ac.jp
Naito
Takafumi
T
Takeyama
Masaharu
M
D000081:Acetamides / Q000494:pharmacology*; D000328:Adult; D000897:Anti-Ulcer Agents / Q000494:pharmacology*; D015740:Calcitonin Gene-Related Peptide / Q000097:blood*; D006801:Humans; D007124:Immunoenzyme Techniques; D008297:Male; D010880:Piperidines / Q000494:pharmacology*; D011725:Pyridines / Q000494:pharmacology*; D012633:Secretin / Q000097:blood*; D013004:Somatostatin / Q000097:blood*
D000081:Acetamides; D000897:Anti-Ulcer Agents; D010880:Piperidines; D011725:Pyridines; D012633:Secretin; C076948:lafutidine; D013004:Somatostatin; D015740:Calcitonin Gene-Related Peptide